Guilherme Rossato de Almeida
机构：AC Camargo Hospital, Dana-Farber Cancer Institute · ORCID：0009-0000-6073-6130
发表论文 35 篇 · 总被引 38 次 · h-index 3
代表论文
- First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC (2025 · Clinical Cancer Research · 被引 9)
- Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report (2026 · Journal of Thoracic Oncology)
- OA01.04: Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors (2026 · Journal of Thoracic Oncology)
- Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer (2026 · Breast Cancer Research and Treatment)
- Total neoadjuvant treatment in locally advanced rectal cancer: A retrospective multicentre cohort analysis in three cancer centres in Brazil. (2026 · Journal of Clinical Oncology)
- Supplementary Figure 5 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC (2025)